Paion’s novel sedation drug, remimazolam, was approved in the US, China, and Japan this year and now the European Medicines Agency is set to decide whether it should be authorized for use across the EU.

German biotech could realize more than $2bn in earnouts under pact with Roivant. Galmed teams with MyBiotics in attempt to optimize clinical response to its Phase III NASH candidate Aramchol.

Stada has appointed general managers for its businesses in Germany and Poland. Meanwhile, US and UK industry associations the AAM and BGMA have announced appointments, Glenmark has added an ex-Teva executive to its board of directors and the MHRA has named a new chair.

Private Company Edition: Several drug developers targeting neurological diseases raised venture capital recently. In addition to Nura Bio, Encoded Therapeutics revealed a $135m series D round. Also, Longwood closed a $170m fund and Flagship launched Omega Therapeutics with $85m.